Navigation Links
Questcor Reports Record Second Quarter Financial Results
Date:7/24/2014

nded June 30, 2014, compared with $12.2 million for the year ago period. The increased R&D expense reflects the Company's ongoing efforts to further build the body of clinical evidence for Acthar, clarify the potential immune-modulating properties of Acthar and Synacthen Depot, and identify mechanisms of action that potentially could be applicable to other inflammatory and auto-immune diseases with high unmet medical needs. R&D expense in the second quarter of 2014 includes an upfront payment of $3.3 million to a third party in connection with a research and development agreement. 

The Company is also identifying new patient populations in which to evaluate both Acthar and Synacthen Depot through exploratory clinical studies. Questcor is presently funding research and development for Acthar in the following indications:

New Indications for Label Enhancement Programs:

  • Amyotrophic Lateral Sclerosis (ALS): Patient enrollment has been completed in a company-sponsored dose-ranging Phase 2 clinical trial to evaluate the safety and tolerability of Acthar in patients with ALS, often referred to as Lou Gehrig's disease. ALS is a life-threatening, progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
  • Diabetic Nephropathy: Enrollment continues in a company-sponsored Phase 2 trial to evaluate the efficacy and safety of Acthar in patients with diabetic nephropathy, one of the most common causes of end-stage renal disease in the United States.
  • Acute Respiratory Distress Syndrome (ARDS): Site selection has been initiated for a Phase 2 study to explore the safety and efficacy of Acthar in patients with ARDS. ARDS is an acute life threatening lung condition that can result from pulmonary and non-pulmonary infections or a multitude of other serious conditions.
  • Clinical Trials Supporting Approved Indications:

  • Idiopathic Membranous Nephropathy: Enrollment continues in
    '/>"/>

  • SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

    Related medicine technology :

    1. Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
    2. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
    3. Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana
    4. Questcor Provides Donation In Support Of Childrens Hospital & Research Center Oakland
    5. Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and Healthways
    6. Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
    7. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
    8. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
    9. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
    10. Questcor Honored as an "Everyday Hero" by NephCure Foundation
    11. Questcor Adds G. Kelly Martin to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... 2015  Following a bipartisan vote in the ... 284, the Medicare DMEPOS Competitive Bidding Improvement Act ... (AAHomecare) released a statement praising the Committee,s work ... legislation. "Today,s mark-up of the Competitive ... Means Committee is a critical step forward for ...
    (Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
    (Date:2/27/2015)... Mass. , Feb. 27, 2015  Boston Scientific ... participate in the Barclays 2015 Annual Healthcare Conference on ... Dan Brennan , executive vice president ... vice president, Investor Relations, will participate in a 25-minute ... host analyst at approximately 1:05 p.m. ET. Following a ...
    Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
    ... 9 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today ... the Company,s Board of Directors. Dr. Sanders brings to ... and professor of medicine. , "We are pleased ... Zola P. Horovitz, Ph.D., Chairman of the Board of BioCryst ...
    ... , LONDON, Dec. 9 ... $1 billion in the European Union (EU), which includes total ... anticholinergics used for disease symptom relief. With the introduction of ... guidelines that call for using dopamine agonists as first-line therapy, ...
    Cached Medicine Technology:BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 2Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 3
    (Date:2/28/2015)... National Sales Solutions , ... and supply chain management for consumer packaged goods ... its award winning solutions for thinning-damaged hair to ... specifically created to combat thinning-damaged hair. Known ... to marrying science with nature to create the ...
    (Date:2/28/2015)... 28, 2015 A case management conference ... that have been filed by law firms including Bernstein ... in March, the Firm notes. , According to ... in the federal litigation will meet on March 13, ... prescription therapy treatments designed to raise levels of the ...
    (Date:2/28/2015)... (PRWEB) February 28, 2015 On Thursday, February ... Make It Easy For Scammers To Steal Your Data , ... get their hands on a DIY phishing kit, or any ... also touched on another important point about how everyone’s cyber ... are often implemented, “like compromising legitimate content management systems or ...
    (Date:2/28/2015)... 2015 Developers of FCPX plugins ... overlay plugin for Final Cut Pro X entitled FCPX Overlay ... Chromatic gives users total control over 6k lens dirt overlays ... Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed to ... interface.” , FCPX Overlay Chromatic Grunge 6K is a resourceful ...
    (Date:2/28/2015)... Aliso Viejo, California (PRWEB) February 28, 2015 ... the release of TransFold Volume 2. A fully customizable ... Pro X. , “TransFold Volume 2 gives users total ... users,” said Christina Austin, CEO of Pixel Film Studios. ... Cut Pro X editor.” , TransFold Volume 2 from ...
    Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2
    ... take place on March 10 in Los Angeles, ... Feb. 8 U.S. Health Disparities,Forum organizer Luis ... on Feb. 12 at 1 p.m. EST to ... and presenters will discuss new opportunities for,preventive care ...
    ... MBF Healthcare,Acquisition Corp. (AMEX: MBH ), a ... it will host an investor,conference call on Friday, ... to,discuss the recently announced signing of a definitive ... (along with its,subsidiaries, "CHS"). Hosting the call from ...
    ... Improved ... Quality of Sleep ... (TSX: DDS;,NASDAQ: DDSS) today announced that its recently completed North ... trazodone (study 04ACL3-001) achieved statistical,significance for the primary efficacy endpoint ...
    ... Offering Period, BASEL, Switzerland, Feb. 8 ... its wholly-owned,subsidiary Rocket Acquisition Corporation has accepted for ... offer for all outstanding,shares of common stock of ... at,$89.50 per share in cash., As of ...
    ... health and ... fitness cruise, RANCHO SANTA MARGARITA, Calif., Feb. 7 ... a 5-day Adventure Boot,Camp Fitness Cruise to the Mexican Riviera porting April 28, ... well as those experiencing the boot camp for the first time., Attendees ...
    ... research showed it greatly boosted pregnancy chances , , THURSDAY, ... fertilization can increase their chances of becoming pregnant by ... a preliminary study suggests. , , About 10 percent ... many opt for in vitro fertilization, in which a ...
    Cached Medicine News:Health News:U.S. Health Disparities Forum to Hold Media Briefing 2Health News:MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc. 2Health News:MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc. 3Health News:MBF Healthcare Acquisition Corp. to Host Investor Conference Call to Review Stock Purchase Agreement Signed With Critical Homecare Solutions Holdings, Inc. 4Health News:Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone 2Health News:Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone 3Health News:Roche Purchases Shares in Tender Offer for Ventana 2Health News:Roche Purchases Shares in Tender Offer for Ventana 3Health News:Roche Purchases Shares in Tender Offer for Ventana 4Health News:QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravo's The Real Housewives of Orange County 2Health News:Acupuncture May Aid In Vitro Fertilization 2Health News:Acupuncture May Aid In Vitro Fertilization 3
    For the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma....
    Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
    For the quantitative in vitro determination of Digitoxin in human serum....
    For the quantitative in vitro determination of Valproic Acid in human serum...
    Medicine Products: